Workshop with Susanna Finlay
Susanna Finlay's research interest include the social impacts of Synthetic Biology.
During the workshops we have looked at study cases and discussed the impact of science on society.
We considered the following issues:
- where the scientists/engineer's responsibilities end?
- should scientists think about their impact when doing research?
For more information, have a look at this website.
Ethical panel with Claire Marris
"iGEM team helps prevent rogue use of synthetic biology"
Virginia Bioinformatics Institute (VBI) at Virginia Tech is working on indetifying pracitical solutions to implement legal reuglations on the commericla distribution of GMOs or DNA sequences.
Algorithms under development assess how similar a specific DNA sequence is to entries in the Centers for Disease Control and Prevention’s Select Agent and Toxin List. Keyword lists help to track down matches and allow for continual fine-tuning of the effectiveness of each search. The students are compiling a database of test cases that allows them to estimate the performance of different screening strategies.
Refrence: Article contains further links to articles on Ethical issues with SynBio iGEM team helps prevent rogue use of synthetic biology
Human Practices Report
The Imperial iGEM project focuses on the design of a system that gives a rapid response, because we noticed that many previous biosensor projects had only achieved relatively slow responses to a stimulus. Our concept is an adaptable, modular and robust fast response system, which is fundamental for modern applications in synthetic biology.
One possible application for this fast response module is in the detection of water-borne parasites. We realised that synthetic biology is rarely used in the fight against neglected tropical diseases (NTDs), and we wanted to be pioneers in this field.
Over 1 billion people - a sixth of the world’s population - suffer from one or more NTD. Despite affecting over 90% of the world’s population, only 10% of worldwide health research funding goes into finding preventative or curative treatment for NTDs. This statistic was published by the Global Health Forum and is now referred to as the ‘10/90 gap’. It occurs because the majority of people affected by them live in developing countries, and so profit margins for NTD drugs are negligible.
NTDs are most commonly found in sub-Saharan Africa and in poor urban settings in LMI countries of Asia and Latin America. The effects of NTDs include long-term disability, disfigurement, impaired childhood growth, adverse pregnancy outcomes and reduced economic productivity. In fact, the effect on worker productivity causes billions of dollars to be lost each year, and retains a country in poverty (Hotez et al, 2006; Molyneux et al, 2005). Added to this problem is that of climate change, which is creating favourable conditions for the growth of many NTDs and their vectors, and so it is expected that in the years to come their effects will be felt all the more gravely.
Schistosomiasis, also known as bilharzia, is an NTD that affects over 200 million people worldwide and has drastic effects on the economic viability of the country in which it is endemic (Sturrock, R. F., 1993). The schistosoma parasite is found in sub-Saharan Africa, Latin America and South-East Asia. It has a complicated lifecycle, involving two hosts; snails and humans and infects humans by breaking through the skin during contact with contaminated water.
In recent years, the treatment of schistosomiasis, especially among schoolchildren, has improved markedly due to the availability of praziquantel for generic production. This drug is effective as a single dose, can be administered by primary healthcare teams and directly affects the schistosoma parasite. It also confers some resistance to the disease after taking it, but re-administration is almost always required. Nevertheless, the parasite is still a major problem and there have been suggestions recently that it is spreading to Europe (Roca, C. et al, 2002) and the US (Adair & Nwaneri, 1999). However, there are emerging cases of drug-resistant strains of schistosoma.
At present, most of the detection of schistosoma is only possible after it has infected the human host. Blood, urine and stool samples can all be checked for the parasite. However, the detection of schistosoma in the local environment has proved extremely problematic, is time-consuming and not appropriate for testing in the field due to cumbersome equipment and the fact that a high level of technical expertise is required.
The infective form, called a cercaria, secretes proteases upon detection of skin. These proteases enable the cercariae to break through the skin barrier and infect the host.
We intend to use these proteases to detect the cercariae, because they can trigger a synthetic signalling pathway in our bacterium.
We have discussed a wide range of ethical, legal and social implications (ELSIs) of our project in both a Human Practices Workshop and an interdisciplinary Human Practices Panel Discussion, which involved synthetic biologists, social scientists and bioartists. This has enabled us to develop our design in response to the resulting suggestions.
There are a number of wide-ranging concerns associated with synthetic biology as a technology. However, worries regarding the regulation of synthetic biology are often exacerbated by the media through the use of provocative language which can result in misleading information. It is essential that the link between researchers and the public be made and that there is a constant dialogue between the two. We believe that it is essential that the wider public be engaged in the early stages of a project development, and not in hindsight.
As with any scientific development, there is always the potential for misuse. We have debated who we think should have access to methods used in synthetic biology. However, using it in its current state, the technology requires huge amounts of expertise, which is only possessed by research institutions and some commercial companies. Nevertheless, it has been proposed that some military organisations may possess sufficient resources to be capable of manipulating some developments for potentially detrimental ends. As synthetic biology develops as a field, the ease with which systems are put together and the level of automation will improve. Technology will become more affordable, especially as there is an ‘open source’ ethos within the field of synthetic biology (this will be discussed in ‘legal factors’).
Biosafety and Environmental factors
Of particular concern is the uncontrolled release, intentional or accidental, of GMOs. The prospect of contaminating groundwater is especially alarming in locations where coordination of water treatment is under-developed. We have considered how uncontrolled release would affect the local environment, and the biodiversity of its ecosystem. Our choice of chassis was B. subtilis, which is a bacterium that can be found in soil and is non-pathogenic. In order to limit the lifetime of the bacterium in the environment, we will integrate certain cassettes at areas in the genome such that they will interfere with essential genes, such as those that are needed to make tryptophan. Therefore, if it were to be released, it would only survive for a limited period of time (this will be tested experimentally to quantify the exact lifetime of the bacterium in different environments and conditions). An additional level of confidence is that a component of the reaction mixture, called catechol, actually kills the bacteria a few hours after it is added. Nevertheless, we are aware that in order for this to occur, the catechol must be added appropriately, and this relies on the correct use of the detection kit. However, if the bacteria were released into the environment without being exposed to catechol, the original genome disruption would be sufficient to ensure that the bacteria would not survive. However, we recognise that biological systems are inherently unpredictable and have the capacity to change. Nevertheless, we believe that the benefits of controlling the population and spread of schistosoma makes this an important project to pursue on the proviso that biosafety issues and environmental impacts are closely monitored, controlled and managed. We advocate continued, regular testing of the bacteria in order to ensure that any mutations, which would result in the deviation from its function, are noticed early and so the problem can be remediated. We would ensure that there are thorough, controlled and longitudinal studies of the effects of the bacteria on a range of environments and seasons, prior to the marketing of the product.
Political factors and regulation
Regulation of the use of synthetic biology is a huge concern of both synthetic biologists and the wider public. We have debated whether regulation should be external or internal, and government-led or –funded. Self-regulation could be an effective way of ensuring that rules are adhered to, but with a lack of external scrutiny, it is unlikely to be sufficient for the public to feel entirely confident about the issues raised. This is due to the difficulty in keeping track of such a diffuse network of researchers (Schmidt, 2008) and the fact there is always the potential for people to ignore the rules. We therefore believe that an international, independent body should monitor organisations working in the field of synthetic biology, and that there should be transparency in all their dealings. At Imperial College London, the GM safety committee is responsible for ensuring that all research adheres to the regulations set down by the Health and Safety Executive (HSE). The first stage in the commencement of a project is the completion of a comprehensive risk assessment, which is submitted to the GM safety committee, which will then (i) approve the risk assessment and (ii) identify control measures. These control measures then need to be put in place. If the GM classification is Class 2 or higher, the project must be discussed with the Director of Occupational Health to determine whether health surveillance is necessary.
A legal framework to control the use and ownership of the developments of synthetic biology is essential in order to establish the open source philosophy. We are aware that copyrights and patents can limit the scope of further research, because information is not accessible or research centres must pay heavily to use such innovations. There are many arguments for the implementation of open source synthetic biology, as opposed to using patenting laws. It has been suggested that open source projects drive innovation within the field, but they can also present huge logistical problems in terms of regulation upon diffusion of the technology (Schmidt, 2008).
There has been extensive media coverage concerning access to medicines and technology in the fight against NTDs. In the majority of cases, strong intellectual property rights (IPR) regulations rule out the generic production of drugs so that no alternative to costly medicines are available. The majority of NTDs occur in developing countries, where healthcare provision is often poor and there are few resources available in terms of NTD medication. Strong IPR regulations for NTD drugs are often seen as unnecessary because pharmaceutical companies will not generate profits because people who can afford the drugs do not need them, and vice versa. This is because NTD incidence is low in developed countries and much higher in LMI countries. Wider access to NTD drugs could be achieved by ensuring that research is available as open source.
We have ensured that the cost of production of the detection kit is low enough to make it affordable to the people who need it. This was achieved by designing a product that is economical to produce and uses inexpensive chemicals. The role of industry in synthetic biology is a controversial one. Industry is driven by profit, and we would like to ensure that no company has a monopoly in any particular area through the ownership of one or more of our modules. In particular, universities are centres of learning, and are not profit-generating businesses. We therefore believe that it is essential that research done at universities is accessible and can be used to benefit others. This could be achieved by making the modules available through open source, or by licensing the modules to different companies so that no one company has a monopoly.
It is very important to us that the people who would benefit from the detection kits have access to them and so they must be affordable and available in appropriate locations. Accessibility to kits depends on the following parameters:
- Distribution & ease of transportation
- Shelf life
- Ease of use
We considered the type of organisation who would distribute the detection kits. This could be done by government organisations and local authorities, which would be ideal because it would allow developing countries to organise and manage their local distribution and use of the kits. However, this may not be the best option if government resources are poor or if there is a threat of corruption. If this were the case, aid programs and NGOs may be in a better position to distribute the kits.
We do not believe that our detection kit on its own can solve the problem of schistosoma. Improved sanitation and education is needed in combination with environmental control of parasites. An assessment of the level of education regarding parasitic infections, in particular schistosoma, such as how to protect against parasitic infection and how to treat them would be necessary to determine where further education was needed. This would be given alongside training in the use of the detection kit to ensure the long-term feasibility of our project, and also to overcome any cultural boundaries there may be. It is also important that we determine the social acceptability of the kits before we finalise the design. During this process, it is possible that we would find that different designs are more appropriate in different settings, and the overall design may be needed to be tailored to a specific community, depending on the setting in which it is implemented.
The benefits to local communities are unlikely to be seen straight away. This is due to the nature of NTDs and their prolonged effects on individuals, and the fact that much of the problem with them is due to socio-economic factors (Hotez et al, 2006; Molyneux et al, 2005). However, as the incidence of, for example, schistosoma decreases, the economic productivity of a particular population will hopefully improve, and this should result in a positive feedback loop where the NTD incidence decreases even further due to the improved economy of a given country.
Due to the constraints imposed by the environment in which most NTDs occur, our detection kit needs to be portable to resource-poor settings, affordable, easy to use and store, and not dangerous if released into the environment. We considered the advantages of targeting the detection kit for use by organisations instead of domestic use. One example is that training would only need to be given to employees of the organisations, and not to whole communities, thus making the system much more viable in terms of cost and time. Also, disposal of the kits was too great an issue in terms of infrastructure; we decided to target it for use by local authorities so that water can be tested in different regions and treated accordingly.
Our project involves taking genes from a pathogenic bacterium, Streptococcus pneumoniae, which is by no means ideal, but an alternative could not be found in a non-pathogenic species. However, the genes are only involved in the competence pathway and not in any pathogenic pathways. Therefore, we do not expect any adverse consequences from using these genes out of context, and we would ensure that testing is done prior to the marketing of our product so that it is certain that no pathogenicity is transferred to our bacterium.
Our choice of chassis B. subtilis, a non-pathogenic bacterium that is present in many environments, such as soil. Using B. subtilis means that the cells can be transported in spore form, allowing them to withstand large temperature extremes. This means that the whole system will be easy to store and transport, and so will be easy to use in resource-poor settings.
We considered different types of output, such as an odour or light. However, the most reliable and the fastest way of getting a response appeared to be by using the C2,3O reaction, which has a colour output. Our only concern about this is that when testing water with a high level of sediment, it may be hard to observe the colour change, which is yellow-orange.
Due to the modular design of the detection kit, there are many other applications that would benefit from a fast response module. There are also many other parasites that could potentially be detected, especially those that use proteases to infect their host, such as hookworm, guinea worm and strongyloides. These could be other potential applications of our system.
Questions from the Human Practices Panel
- Why would detecting schistosoma be useful?
In deprived rural communities, where resources are limited and healthcare provision is poor, a detection system for parasites could allow the large-scale treatment of water systems by using simple, harmless chemicals. It might also increase awareness of the presence of the parasite, and so people in the surrounding areas can be advised to let the water stand for 24 hours before use (in which time the cercariae will die) or to use an alternative source of water, if possible.
- What is currently being used to detect schistosoma in water?
The systems currently in use for detecting schistosoma in the field require huge amounts of technical expertise, are expensive, time-consuming and therefore unsuitable for use in the field. Some examples include filtration and RT-PCR. It is much easier to detect the parasite after it has infected a human, by testing stool or urinary samples with microscopy or bloody with an antibody test.
- What are the chances of the schistosoma protease genes mutating, resulting in different proteases which our system can no longer detect?
This is very unlikely, because the proteases are vital for the entry of the cercariae into the human body. If the specificity of these changed, they would not be able to invade the body and as a consequence, the cercariae would die within 24 hours. It is unlikely that the cercariae would develop a new method of infection because
- Why not just improve sanitation?
While this would be an ideal solution, it represents a significant logistical problem, especially in rural settings. Among the 8 Millenium Development Goals for 2015 set out by WHO, basic sanitation features as a key factor in the fight to combat extreme poverty. The target is that by 2015, only 23% of the population will be living without improved sanitation. However, at the current rate of progress, the projected figure for 2015 is currently 36%, meaning that an extra 1 billion people who should benefit from the MDGs will miss out (WHO/UNICEF, 2010). This shortfall in the number of people who have access to improved sanitation is mostly due to poor infrastructure, lack of sustainability and ineffective financial aid. Therefore, we propose that a combination of approaches is needed to compliment the use of the detection kit. This could include enhanced sanitation and improved access to essential medicines and education where needed.
- Why do we need a fast response?
For synthetic biology to be of real use in this age, and in applications such as parasite detection, it is fundamental that we get a fast response. Nowadays people expect results quickly, and the public could easily not see the potential that synthetic biology has if the results were not seen on a fast enough timescale. NTDs are most prevalent in remote settings, where resources are limited and vast areas of land are needed to be tested as quickly as possible. Therefore, a quick output would facilitate a greater frequency of testing.
Other ideas: -School workshop (A-level students: talking about SynBio and a workshop where they can come up with ideas/applications etc) -Interviews/surveys with public -Meet with Imperial Innovations Plc: how would they patent it? -Meeting/dialogue with people who work in development -Panel discussion/debate. Possible questions: What are the consequences of seeing life as nothing more than parts to be assembled? Is nature too complex to be treated as parts? Do synthetic organisms have less intrinsic value than natural ones? Who should be responsible for the direction that synthetic biology takes?
Abbreviations: C2,3O Catechol 2,3 Dioxygenase; ELSI Ethical, legal and social implications; FDI Foreign direct investment; GMO Genetically modified organism; HSE Health and Safety Executive; IPR Intellectual property rights; MDG Millennium development goals; NTD Neglected tropical disease; R & D Research and development; WHO World Health Organisation;
References: Adair R, Nwaneri O. (1999) Communicable disease in African immigrants in Minneapolis. Arch Intern Med; 159: 83-85 Balmer, A. & Martin, P. (2008) Synthetic Biology: Social and Ethical Challenges www.syntheticbiology.org Accessed on 05/08/10 Check, E. (2002) ‘Venter aims for maximum impact with minimal genome,’ Nature Vol. 420 (28th November): 350 Nature Editorial (2008) ‘Pathways to Security,’ Nature Vol. 445 (25 Sept): 43 Hotez, P. J., Ottesen, E., Fenwick, A., & Molyneux, D. H. (2006) The neglected tropical diseases: The ancient afflictions of stigma and poverty and the prospects for their integrated control and elimination. Hot topics in infection and immunity in children III. New York: Kluwer Academic/Plenum Publishers. Johnson, B. (2010) Synthetic Biology Dialogue Molyneux, D. H, Hotez, P. J. & Fenwick, A. (2005) Rapid-Impact Interventions: How a Policy of Integrated Control for Africa’s Neglected Tropical Diseases Could Benefit the Poor PLoS Medicine. Roca C, Balanzo X, Gascon J, Fernandez-Roure JL, Vinuesa T, Valls ME, Sauca G, Corachan M. Comparative, clinicoepidemiologic study of Schistosoma mansoni infections in travellers and immigrants in Spain. Eur J Clin Microbiol Infect Dis 2002; 21: 219-223 http://www.who.int/schistosomiasis/en/ accessed on 14/08/10 Schmidt, M. (2008) Diffusion of synthetic biology: a challenge to biosafety Syst Synt Biol www.synbiosafe.eu accessed on 16/08/10 Sturrock, R. F. (1993) The control of schistosomiasis. Second report of the WHO expert committee Geneva: World Health Organisation Vol II WHO/UNICEF (2010) Progress on sanitation and drinking-water 2010 update